Active implantable medical devices under Part II of the UK Medical Devices Regulations 2002 — definition, scope, Essential Requirements, conformity assessment, and the distinction from Class III general medical devices.
How MHRA approaches products that sit on the boundary between medical devices and other regulatory frameworks — medicines, cosmetics, biocides — and how drug-device combination products are regulated under the UK Medical Devices Regulations 2002.
How CE marking is accepted on the Great Britain market under transitional arrangements — the current deadline of 30 June 2030, what devices are covered, the conditions that apply, and what manufacturers must still do even when relying on CE marking for GB access.
How to structure an Essential Requirements checklist and traceability matrix for a UK MDR 2002 technical file — with a worked example framework, common pitfalls, and guidance on maintaining the checklist throughout the device lifecycle.
Overview of the four risk classes for general medical devices under the UK Medical Devices Regulations 2002 — what defines each class, UKAB requirements, conformity assessment routes, and practical examples of devices in each class.
How manufacturers of Class I medical devices self-declare conformity under the UK MDR 2002 — the process, required documentation, MHRA registration, and the three Class I sub-categories that require partial UK Approved Body involvement.
The UK Approved Body conformity assessment routes for Class IIa, IIb, and III medical devices under Schedule 3 of the UK MDR 2002 — QMS audits, type examination, design dossier assessment, and the certificate types issued.
A rule-by-rule walkthrough of all 18 classification rules in Schedule 2 of the UK Medical Devices Regulations 2002, with the device characteristics each rule targets and practical examples.
What clinical evaluation entails for medical devices under the UK MDR 2002 — the clinical evaluation process, literature-based evidence, equivalent device approach, clinical investigations, and ongoing post-market clinical follow-up (PMCF).
How the clinical evaluation is presented and referenced in the medical device technical file under UK MDR 2002 — the Clinical Evaluation Report, its relationship to other technical file elements, and post-market update requirements.
How to conduct a clinical investigation of a medical device in the UK — MHRA notification, ethics committee approval, protocol requirements, adverse event reporting, and post-investigation obligations under the UK MDR 2002.
How conformity assessment works under the UK MDR 2002 — the available routes by device class, the role of UK Approved Bodies, how to select the right route, and what the process produces.
The regulatory requirements for custom-made medical devices under the UK MDR 2002 — definition, who qualifies, the modified conformity assessment pathway, required documentation, and the distinction from standard devices adapted for individual patients.
The specific design and construction Essential Requirements in Section II of Schedule 1 of the UK Medical Devices Regulations 2002 — covering chemical and biological properties, infection control, measuring function, radiation, software, and labelling.
The design and manufacturing information required in a medical device technical file under the UK MDR 2002 — design inputs and outputs, verification and validation, manufacturing process documentation, and quality system records.
What the device description and specification section of the technical file must contain under the UK MDR 2002 — product identification, intended purpose, design specifications, variants, and accessories.
What information must be provided at the device level when registering with MHRA — device descriptions, classification, certificate references, and the distinction between registering a device family vs individual models.
Regulatory requirements for medical devices manufactured in Great Britain for export only — what obligations apply, what obligations do not apply, MHRA's position on export certificates, and compliance with the destination country's regulatory framework.
How medical devices that incorporate a medicinal substance are regulated under the UK MDR 2002 — the device-led vs medicine-led determination, Class III classification, the role of MHRA, and practical examples including drug-eluting stents and antibiotic-impregnated devices.
The Essential Requirements under the UK Medical Devices Regulations 2002 — what they are, where they are found (Schedule 1 and Schedule 1A), how to demonstrate conformity, the role of UK-designated standards, and the checklist and traceability matrix approach.
A detailed examination of the six general Essential Requirements in Section I of Schedule 1 of the UK Medical Devices Regulations 2002 — the safety, performance, risk management, and design principles that apply to every medical device placed on the GB market.
How medical device classification works under the UK Medical Devices Regulations 2002 — the rule-based system for general devices (Classes I, IIa, IIb, III), active implantable devices (AIMD), and IVDs (List A, List B, Self-test, General) — and why classification determines everything else.
Medical devices incorporating human tissue or cells — how they are regulated under the UK MDR 2002 in combination with the Human Tissue Act 2004 and MHRA/HTA oversight, and the distinction between device-led and transplant/therapy-led products.
Regulatory requirements specific to implantable medical devices under the UK MDR 2002 — classification, additional Essential Requirements, implant cards, long-duration traceability, and vigilance obligations.
IVD medical device classification under Part III of the UK Medical Devices Regulations 2002 — Annex II List A, Annex II List B, self-test devices, and general IVDs, with conformity assessment requirements for each category and comparison with EU IVDR Class A–D.
The Essential Requirements specific to in vitro diagnostic medical devices under Schedule 1A of Part III of the UK Medical Devices Regulations 2002 — analytical performance, clinical performance, labelling, and instructions for use requirements.
A stage-by-stage overview of the regulatory lifecycle of a medical device in Great Britain — from concept and classification through pre-market conformity assessment and MHRA registration to post-market surveillance, vigilance, and end-of-life obligations under the UK MDR 2002.
Performance evaluation requirements for IVD medical devices under Part III of the UK MDR 2002 — analytical performance, clinical performance, scientific validity, and the Performance Evaluation Report (PER).
Step-by-step guide to completing device registration via the MHRA Submissions portal — account setup, registration workflow, required information, and common issues.
How to apply ISO 14971 risk management to satisfy Essential Requirement 2 of the UK MDR 2002 — the risk management plan, hazard identification, risk estimation, risk controls, residual risk evaluation, and the lifecycle requirement to keep the risk file updated.
The regulatory framework for single-use medical devices in the UK — mandatory labelling, the prohibition on reprocessing and reuse, and the specific requirements for manufacturers who place reprocessed single-use devices on the GB market.
Detailed guidance on software as a medical device (SaMD) and artificial intelligence/machine learning (AI/ML) medical devices under the UK MDR 2002 — qualification, classification, technical documentation requirements, and MHRA's AI Change Programme.
How standalone software is classified as a medical device under the UK Medical Devices Regulations 2002 — the qualification test, applicable classification rules, MHRA guidance on AI and machine learning, and comparison with the EU MDR/MDCG approach.
How systems and procedure packs are regulated under the UK MDR 2002 — the definition of a system or procedure pack, the obligations on the person assembling the pack, the statement required, and when a pack constitutes a new medical device.
What the technical file must contain under UK MDR 2002, how it is structured, the difference between a technical file and a design dossier, UKAB access requirements, and how the technical file must evolve throughout the device lifecycle.
The Unique Device Identification (UDI) system for medical devices in Great Britain — current requirements, MHRA's implementation timeline, UDI structure (DI and PI), and how UK UDI relates to EU UDI requirements.
What a UK Declaration of Conformity is, what it must contain, who signs it, how it differs from an EU Declaration of Conformity, and how to maintain it throughout the device lifecycle under the UK MDR 2002.
How to correctly apply the UKCA mark under UK MDR 2002 — who can affix it, what it must look like, where it must appear, the UKAB identification number, and the transitional CE marking acceptance for the GB market until 30 June 2030.
How clinical data generated outside the UK — from EU, US, Japanese, Australian, Canadian, or other investigations and studies — can be used to support clinical evaluation under the UK MDR 2002.
Which entities are required to register with MHRA before placing medical devices on the Great Britain market — manufacturers, UK Responsible Persons, and authorised representatives — and the consequences of failing to register.